Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Comparative Effects of Autogenic Inhibition vs Reciprocal Inhibition in Patients With Lower Cross Syndrome

18 września 2026 zaktualizowane przez: Foundation University Islamabad

This randomized controlled trial aims to compare the effectiveness of Autogenic Inhibition Muscle Energy Technique (MET) and Reciprocal Inhibition MET in individuals with Lower Crossed Syndrome. Participants will be randomly assigned to two intervention groups. One group will receive Autogenic Inhibition MET, while the other will receive Reciprocal Inhibition MET for the iliopsoas, rectus femoris, and erector spinae muscles. Both groups will also perform the same standardized strengthening exercises targeting the transversus abdominis, gluteus maximus, and gluteus medius muscles to improve muscle balance and functional outcomes.

Przegląd badań

Szczegółowy opis

Participants who meet the eligibility criteria and provide informed consent will be randomly allocated into two experimental groups using a randomization method. The intervention will be carried out over a period of six weeks, with three treatment sessions per week, making a total of 18 sessions for each participant. Before the commencement of each treatment session, all participants will receive a 10-minute hot pack application over the lumbar region to promote muscle relaxation, reduce soft tissue stiffness, and prepare the muscles for manual therapy. Following the hot pack, participants will receive the assigned Muscle Energy Technique (MET) according to their respective group.

Participants in Experimental Group 1 will receive Autogenic Inhibition Muscle Energy Technique (Modified Post-Facilitation Stretch Protocol) targeting the iliopsoas, rectus femoris, and erector spinae muscles. The therapist will position the involved muscle at its initial barrier, after which the participant will perform an isometric contraction of approximately 20-30% of maximal effort for 7-10 seconds against the therapist's resistance. After relaxation, the muscle will be gently stretched to the new barrier and the stretch will be maintained for 30 seconds. This procedure will be repeated 3-5 times for each muscle during every treatment session.

Participants in Experimental Group 2 will receive Reciprocal Inhibition Muscle Energy Technique for the same muscle groups. The therapist will position the muscle at the initial barrier, and the participant will perform an isometric contraction of the antagonist muscle using approximately 20-30% of maximal effort for 7-10 seconds. Following relaxation, the therapist will move the muscle to the new barrier and maintain the stretch for 30 seconds. The technique will also be repeated 3-5 times for each targeted muscle during every treatment session.

Both groups will follow an identical strengthening exercise program to address the weak muscles commonly associated with Lower Crossed Syndrome. The strengthening program will target the transversus abdominis, gluteus maximus, and gluteus medius muscles using progressive therapeutic exercises prescribed according to the participant's tolerance. During the first two weeks, the intervention will primarily emphasize improving flexibility and reducing muscle tightness through the assigned MET. From Week 3 to Week 6, participants will continue receiving their allocated MET while simultaneously performing the strengthening exercises to restore muscle balance, improve lumbopelvic stability, and enhance functional performance. Exercise intensity and repetitions will be progressed gradually throughout the intervention while maintaining proper technique and patient comfort.

The treatment duration, session frequency, hot pack application, strengthening protocol, therapist supervision, and progression of exercises will remain identical for both groups. The only difference between the two groups will be the type of Muscle Energy Technique employed-Autogenic Inhibition MET in Experimental Group 1 and Reciprocal Inhibition MET in Experimental Group 2. Outcome measures will be recorded before and after completion of the intervention period to evaluate the comparative effectiveness of both treatment approaches in improving pain, muscle flexibility, lumbar range of motion, posture, and functional disability among individuals with Lower Crossed Syndrome.

Typ studiów

Interwencyjne

Zapisy (Szacowany)

46

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Kopia zapasowa kontaktu do badania

Lokalizacje studiów

    • Punjab Province
      • Islamabad, Punjab Province, Pakistan, 44000
        • Rekrutacyjny
        • Foundation University College of Physical Therapy
        • Kontakt:

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

19 lat do 35 lat (Dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria

  • Age 19-35 years.
  • Both genders will include in this study.
  • According to Janda's Approach, Clinical diagnosis of LCS based on ≥3 positive clinical tests.
  • Patient with positive modified Thomas test, Patients with a positive testing of prone hip extension test, Patients with a positive test of trunk flexion test, Patients with tight erector spinae muscles.
  • Participants with no lumbar pain to moderate lumbar pain (NPRS0-6) will be included.
  • Painless movement and activity.
  • Pain only produced by sustained loading in relevant position, which is then relieved after maintaining a corrected posture for 5 minutes, indicating posture-related pain.

Exclusion Criteria

  • Leg symptoms when walking, eased in flexion (Signs of stenosis)
  • Pain due to repetitive movement
  • Lumbar Radiculopathy
  • Neurological Symptoms (Paresthesia/numbness)
  • Structural deformity (Kyphosis, lordosis, scoliosis, spondylosis, spondylolysis, spondylolisthesis)

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Aktywny komparator: Autogenic Inhibtion (Group A)

Group A will receive Autogenic inhibition using PFS, preceded by 10 minutes heating pad application. 30% Isometric contraction(7-10 sec), followed by relaxation & 30 sec stretch, will be repeated 3-5 time. From Weeks 3-6, strenghtening exercises for hip extensors & Transverse Abdominis will be performed.

Experimental Group 1 will receive MET based on autogenic inhibition using Modified Post-Facilitation Stretch (PFS) for the iliopsoas, rectus femoris, and erector spinae. For the iliopsoas, subjects will assume modified Thomas position and perform a 30% isometric contraction for 7-10 seconds, followed by relaxation and hip extension stretching for 30 seconds. For rectus femoris, the procedure will be performed in modified Thomas position with knee flexion, followed by hip extension and knee flexion stretching for 30 seconds. For erector spinae, subjects will sit with legs hanging and arms crossed, perform a 30% isometric contraction for 7-10 seconds, followed by trunk flexion for 30 seconds. Each technique will include 30-second rest and 3-5 repetitions. From the 3rd to 6th week, strengthening will include TA activation, gluteus maximus bridging, and gluteus medius abduction.

Eksperymentalny: Reciprocal Inhibition (Group B)

Group B will receive Reciprocal Inhibition using using MET,preceding by a 10 minute heating pad application. A 30% isometric contraction(7-10 sec) of antagonist muscle, followed by relaxation & 30-60sec passive stretch, will be repeated 3-5 times. From 3-6 weeks strenghening exercises for hip extensor & transverse abdominis will be performed.

Experimental Group 2 will receive MET based on reciprocal inhibition for the iliopsoas, rectus femoris, and erector spinae. For the iliopsoas, subjects will assume modified Thomas position and perform a 30% isometric contraction of the gluteus maximus for 7-10 seconds, followed by relaxation and passive hip extension stretching for 30-60 seconds. For rectus femoris, subjects will assume modified Thomas position followed by a 30% isometric hamstring contraction for 7-10 seconds and passive stretching into hip extension with knee flexion for 30-60 seconds. For Erector Spinae, subjects will sit with legs hanging and perform a 30% isometric transverse abdominis contraction for 7-10 seconds, followed by trunk flexion for 30-60 seconds. From the 3rd to 6th week, strengthening will include TA activation, gluteus maximus bridging, and gluteus medius abduction.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Lumbar Extensor Muscle Length
Ramy czasowe: Baseline & after 6 weeks of intervention.

The Modified Schober's Test will be used to assess lumbar extensor muscle length and lumbar spine mobility. The increase in distance between standardized spinal landmarks during maximal forward flexion will be measured and recorded in centimeters (cm). A greater increase in distance indicates greater lumbar extensor flexibility or length.

Baseline & after 6 weeks of intervention.
Functional Movement dysfunction
Ramy czasowe: Baseline and after 6 Weeks of intervention.

Functional Movement Screen will be used to assess functional movement dysfunction. It consists of seven tests, scored on a 0-3 scale, with a total score ranging from 0 to 21. Lower scores indicate greater movement dysfunction.

Baseline and after 6 Weeks of intervention.
Back Pain
Ramy czasowe: Baseline and after 6 Weeks of intervention.

Pain intensity will be assessed using the Numerical Pain Rating Scale, ranging from 0 (no pain) to 10 (worst possible pain). Participants reporting pain intensity scores of 0-6 on the NPRS will be eligible for inclusion in the study.

Baseline and after 6 Weeks of intervention.
Functional Disability
Ramy czasowe: Baseline and after 6 Weeks of intervention

Functional disability will be assessed using the Oswestry Disability Index (ODI), a 10-item questionnaire, with each item consisting of six response options.

Baseline and after 6 Weeks of intervention
Lumbar Range Of Motion
Ramy czasowe: Baseline and after 6 Weeks of invention

Lumbar spine range of motion (ROM) will be assessed using inclinometer, including lumbar flexion, extension, and lateral flexion. Lumbar ROM will be determined by measuring the difference between the readings obtained at the T12 and S2 spinal landmarks.

Baseline and after 6 Weeks of invention

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

12 lutego 2026

Zakończenie podstawowe (Szacowany)

18 grudnia 2026

Ukończenie studiów (Szacowany)

18 stycznia 2027

Daty rejestracji na studia

Pierwszy przesłany

18 września 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

18 września 2026

Pierwszy wysłany (Rzeczywisty)

24 września 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

24 września 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

18 września 2026

Ostatnia weryfikacja

1 września 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • FUI/FUCP/CTR/MSMSK/MomnaKhadim

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj